Trends in electronic cigarette use in England
Slides from Prof Robert West's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
E-Cigarette Summit Speaker: Dr Lynne DawkinsLindsay Fox
Slides from Dr Lynne Dawkins' presentation at the E-Cigarette Summit, London November 12, 2013. Electronic Cigarettes: What are they, and are they effective?
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Proposed Changes to How E-Cigarettes Are Regulated - Prof. Linda BauldLindsay Fox
Proposed changes to how e-cigarettes are regulated: UK and EU context
Slides from Prof. Linda Bauld's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Research on Safety of Electronic Cigarettes - Dr. Konstantinos FarsalinosLindsay Fox
Research on Safety of Electronic Cigarettes
Slides from Dr. Konstantinos Farsalinos' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
The Regulation of Nicotine-Containing Products - Jeremy Mean - E-Cigarette Su...Lindsay Fox
The regulation of Nicotine-Containing Products (NCPs)
Slides from Jeremy Means' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
E-Cigarette Summit Speaker: Dr. Jacques Le HouezecLindsay Fox
Nicotine safety in the context of e-cigarette use and tobacco dependence
Slides from Dr. Jacques Le Houezec's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
E-Cigarette Summit Speaker: Dr Lynne DawkinsLindsay Fox
Slides from Dr Lynne Dawkins' presentation at the E-Cigarette Summit, London November 12, 2013. Electronic Cigarettes: What are they, and are they effective?
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Proposed Changes to How E-Cigarettes Are Regulated - Prof. Linda BauldLindsay Fox
Proposed changes to how e-cigarettes are regulated: UK and EU context
Slides from Prof. Linda Bauld's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Research on Safety of Electronic Cigarettes - Dr. Konstantinos FarsalinosLindsay Fox
Research on Safety of Electronic Cigarettes
Slides from Dr. Konstantinos Farsalinos' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
The Regulation of Nicotine-Containing Products - Jeremy Mean - E-Cigarette Su...Lindsay Fox
The regulation of Nicotine-Containing Products (NCPs)
Slides from Jeremy Means' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
E-Cigarette Summit Speaker: Dr. Jacques Le HouezecLindsay Fox
Nicotine safety in the context of e-cigarette use and tobacco dependence
Slides from Dr. Jacques Le Houezec's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
What is wrong (and right) about the Tobacco Products Directive approach to E-...Clive Bates
These are the visual aids for my talk on the truly dreadful European Union Tobacco Products Directive as it applies to e-cigarettes, and why Totally Wicked has a legal case against it.
Nicotina - Reducción de riesgos y daños / Nicotine - Risk and Harm ReductionClive Bates
Presentación en línea para el seminario de políticas en Colombia enfocado en políticas de vapeo y consecuencias no deseadas /
Presentation online for policy seminar in Colombia focussed on vaping policy and unintended consequences
Slides on the current situation with global cigarette consumption and trends, and how new nicotine products could change things.
See blog at: http://www.clivebates.com/?p=2782 for more commentary.
Reduced nicotine rule: a terrible idea to be pursued relentlesslyClive Bates
Presentation to FDLI conference 26th October 2017. For more information and full report see: https://www.clivebates.com/fda-wants-to-reduce-nicotine-in-cigarettes-what-could-possibly-go-wrong-and-right/
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...Lindsay Fox
How E-Cigarettes Should be Regulated
Slides from Jean-François ETTER's presentation at the E-Cigarette Summit, London November 12, 2013.
Summary of evidence:
1. E-cigarettes are used by current and former smokers, as a cheaper and safer alternative to tobacco
2. Most users report that e-cigs help them quit or reduce smoking
3. Regular or daily use in non-smokers has not been documented so far
4. E-cigs are less addictive and less toxic than cigarettes
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Effects of alternative nicotine delivery systems on cigarette consumption and...Clive Bates
Presentation at SRNT-Europe Conference September 2019 on the impact of vaping and other reduced-risk products on cigarette sales and smoking prevalence.
To see the fully animated version, please download.
E-Cigarette Summit Speaker: Clive BatesLindsay Fox
Regulation: when less is more
Slides from Clive Bates' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Regulation of Tobacco Harm Reduction - GFN 2018 ScholarsClive Bates
Global Forum on Nicotine 2018 Scholars meeting on regulation discusses optimum regulation using 4 Ps of marketing framework to consider risk-proportionate regulation
NYU College of Global Health - E-cigarette seminar - New YorkClive Bates
E-Cigarettes: The Tectonic Shift in Nicotine and Tobacco Consumption: Opportunity or Threat to Saving Lives?
Clive Bates
Friday, October 19, 2018
NYU School of Law, Greenberg Lounge
40 Washington Square South, New York, New York
Overview of electronic cigarettes including history, components, safety and adverse events, efficacy in smoking cessation, pharmacokinetics and epidemiology. This presentation was originally delivered to 2nd year pharmacy students as part of a two semester class on pharmacology and toxicology.
Regulation: why less is more... E-cigarette Summit 12 November 2013 - Clive B...Clive Bates
My presentation covering why 'less is more' when it comes to regulating low risk alternatives to cigarettes such as e-cigarettes. Too much regulation will limit appeal, increase costs, raise barriers to entry and inhibit innovation. I also urge a focus on the huge potential benefits of low-risk alternatives to smoking instead of obsession over minor or implausible risks.
Is nicotine reduction a viable policy for tobacco control? No, Definitely not...Clive Bates
My critique of the proposal that regulators should reduce the concentration of nicotine in cigarettes to a sub-addictive level - effectively a prohibition of cigarettes as we know them.
Presentation at SRNT 2017 in Florence, Italy on 8 March 2017.
What is wrong (and right) about the Tobacco Products Directive approach to E-...Clive Bates
These are the visual aids for my talk on the truly dreadful European Union Tobacco Products Directive as it applies to e-cigarettes, and why Totally Wicked has a legal case against it.
Nicotina - Reducción de riesgos y daños / Nicotine - Risk and Harm ReductionClive Bates
Presentación en línea para el seminario de políticas en Colombia enfocado en políticas de vapeo y consecuencias no deseadas /
Presentation online for policy seminar in Colombia focussed on vaping policy and unintended consequences
Slides on the current situation with global cigarette consumption and trends, and how new nicotine products could change things.
See blog at: http://www.clivebates.com/?p=2782 for more commentary.
Reduced nicotine rule: a terrible idea to be pursued relentlesslyClive Bates
Presentation to FDLI conference 26th October 2017. For more information and full report see: https://www.clivebates.com/fda-wants-to-reduce-nicotine-in-cigarettes-what-could-possibly-go-wrong-and-right/
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...Lindsay Fox
How E-Cigarettes Should be Regulated
Slides from Jean-François ETTER's presentation at the E-Cigarette Summit, London November 12, 2013.
Summary of evidence:
1. E-cigarettes are used by current and former smokers, as a cheaper and safer alternative to tobacco
2. Most users report that e-cigs help them quit or reduce smoking
3. Regular or daily use in non-smokers has not been documented so far
4. E-cigs are less addictive and less toxic than cigarettes
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Effects of alternative nicotine delivery systems on cigarette consumption and...Clive Bates
Presentation at SRNT-Europe Conference September 2019 on the impact of vaping and other reduced-risk products on cigarette sales and smoking prevalence.
To see the fully animated version, please download.
E-Cigarette Summit Speaker: Clive BatesLindsay Fox
Regulation: when less is more
Slides from Clive Bates' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Regulation of Tobacco Harm Reduction - GFN 2018 ScholarsClive Bates
Global Forum on Nicotine 2018 Scholars meeting on regulation discusses optimum regulation using 4 Ps of marketing framework to consider risk-proportionate regulation
NYU College of Global Health - E-cigarette seminar - New YorkClive Bates
E-Cigarettes: The Tectonic Shift in Nicotine and Tobacco Consumption: Opportunity or Threat to Saving Lives?
Clive Bates
Friday, October 19, 2018
NYU School of Law, Greenberg Lounge
40 Washington Square South, New York, New York
Overview of electronic cigarettes including history, components, safety and adverse events, efficacy in smoking cessation, pharmacokinetics and epidemiology. This presentation was originally delivered to 2nd year pharmacy students as part of a two semester class on pharmacology and toxicology.
Regulation: why less is more... E-cigarette Summit 12 November 2013 - Clive B...Clive Bates
My presentation covering why 'less is more' when it comes to regulating low risk alternatives to cigarettes such as e-cigarettes. Too much regulation will limit appeal, increase costs, raise barriers to entry and inhibit innovation. I also urge a focus on the huge potential benefits of low-risk alternatives to smoking instead of obsession over minor or implausible risks.
Is nicotine reduction a viable policy for tobacco control? No, Definitely not...Clive Bates
My critique of the proposal that regulators should reduce the concentration of nicotine in cigarettes to a sub-addictive level - effectively a prohibition of cigarettes as we know them.
Presentation at SRNT 2017 in Florence, Italy on 8 March 2017.
India - Economic Times - Consumer Freedom Conclave - 24 Feb 2022Clive Bates
Tobacco harm reduction: the biggest public health win of the 21st Century?
1. Tobacco harm reduction
2. Risk communication
3. Policymaking
4. Cause of opposition
5. Innovation
In South Africa, we’re concerned about the burden of tobacco and especially about the tactics adopted by the tobacco industry to target youth. Research shows tobacco use is often initiated and established during adolescence and young adulthood.”
Smoking remains a major preventable cause of disease and premature death globally. Read more http://www.cansa.org.za/avoid-tobacco/
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
1. Trends in electronic cigarette use in
England
Robert West
Emma Beard
Jamie Brown
University College London
www.smokinginengland.info
2. Declaration of competing interest
• I undertake research and consultancy for
companies that develop and manufacture
smoking cessation medicines and licensed
nicotine products
• I am a trustee of the charity, QUIT
• I am an honorary co-director of the National
Centre for Smoking Cessation and Training
• My salary and most of my research is funded by
Cancer Research UK
2
3. Methods
• Monthly household surveys
• Each month involves a new representative
sample of ~1800 respondents; smokers ~450
• Data collected on electronic cigarettes since
second quarter 2011
• Fidler, et al., 2011. 'The smoking toolkit study': a
national study of smoking and smoking
cessation in England. BMC Public Health 11:479
• For more info see www.smokinginengland.info
3
4. Percent of smokers and recent exsmokers
Prevalence of electronic cigarette use
50
45
40
35
30
25
20
15
10
5
0
N=9,244 adults who smoke or who stopped in the past year
Any
Daily
4
6. Prevalence of nicotine products while
smoking
50
Percent of smokers
45
40
35
30
25
20
15
10
5
0
N=8,619 smokers
E-cigs
NRT
All nicotine
6
7. Prevalence of nicotine products in
recent ex-smokers
50
Percent of ex-smokers
45
40
35
30
25
20
15
10
5
0
N=532 adults who stopped in the past year
E-cigs
NRT
All nicotine
7
8. Aids used in most recent quit attempt
50
Percent of smokers trying to stop
45
40
35
30
25
20
15
10
5
0
N=4,164 adults who smoke and tried to stop or who stopped in the past year
E-cigs
NRT OTC
NRT Rx
Champix
Beh'l supp
8
10. Percentage trying to quit in past 3m
Quit attempts
50
45
40
35
30
25
20
15
10
5
0
N=11,916 adults who smoked or who stopped in the past 3 months
10
11. Percent who have smoked in the past
year who do not smoke now
Quitting
10
9
8
7
6
5
4
3
2
1
0
N=11,919 adults who smoked in the past year
p=0.004 for increase
11
12. Percent smoking cigs or using nicotine
Prevalence of nicotine/cigarette use
25
p-0.005 for decrease
20
15
10
p-0.001 for decrease
Cigarettes
Nicotine or cigarettes
5
0
N=54,107 adults
12
13. The nicotine/cigarette market
Per capita daily consumption
3
2.5
2
1.5
1
Nicotine
Cigarettes
0.5
0
N=42,347 adults
Nicotine data only from last year smokers
nondaily nicotine: <1 pw=0.1, 1+ pw=0.5
13
14. Conclusions
• An estimated 1 in 6 smokers and recent ex-smokers use
electronic cigarettes and 1 in 10 use them daily
• Almost 1 in 3 quit attempts involve use of electronic
cigarettes
• There has been a decrease in use of other aids to
smoking cessation
• Motivation to stop smoking has increased slightly
• Quit rates have increased slightly
• Per capita cigarette consumption has shrunk but per
capita consumption of all nicotine products appears to
have shrunk less
14